171 related articles for article (PubMed ID: 15621684)
1. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model.
Kaul G; Amiji M
J Drug Target; 2004; 12(9-10):585-91. PubMed ID: 15621684
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies.
Kaul G; Amiji M
Pharm Res; 2005 Jun; 22(6):951-61. PubMed ID: 15948039
[TBL] [Abstract][Full Text] [Related]
3. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery.
Kaul G; Amiji M
Pharm Res; 2002 Jul; 19(7):1061-7. PubMed ID: 12180540
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice.
Kommareddy S; Amiji M
J Pharm Sci; 2007 Feb; 96(2):397-407. PubMed ID: 17075865
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies.
Shenoy D; Little S; Langer R; Amiji M
Pharm Res; 2005 Dec; 22(12):2107-14. PubMed ID: 16254763
[TBL] [Abstract][Full Text] [Related]
7. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles.
Kaul G; Amiji M
J Pharm Sci; 2005 Jan; 94(1):184-98. PubMed ID: 15761942
[TBL] [Abstract][Full Text] [Related]
8. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
Shenoy DB; Amiji MM
Int J Pharm; 2005 Apr; 293(1-2):261-70. PubMed ID: 15778064
[TBL] [Abstract][Full Text] [Related]
9. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
10. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
11. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
12. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
[TBL] [Abstract][Full Text] [Related]
13. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses.
Madan J; Dhiman N; Sardana S; Aneja R; Chandra R; Katyal A
Anticancer Drugs; 2011 Jul; 22(6):543-55. PubMed ID: 21471809
[TBL] [Abstract][Full Text] [Related]
14. A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.
Lupi M; Colombo C; Frapolli R; Ferrari R; Sitia L; Dragoni L; Bello E; Licandro SA; Falcetta F; Ubezio P; Bigini P; Salmona M; D'Incalci M; Morbidelli M; Moscatelli D
Nanotechnology; 2014 Aug; 25(33):335706. PubMed ID: 25074670
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice.
Xu J; Gattacceca F; Amiji M
Mol Pharm; 2013 May; 10(5):2031-44. PubMed ID: 23544877
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
17. Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: an in vitro and in vivo analysis.
Narayanan D; M G G; H L; Koyakutty M; Nair S; Menon D
Nanomedicine; 2013 Aug; 9(6):818-28. PubMed ID: 23428986
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting.
Brigger I; Morizet J; Aubert G; Chacun H; Terrier-Lacombe MJ; Couvreur P; Vassal G
J Pharmacol Exp Ther; 2002 Dec; 303(3):928-36. PubMed ID: 12438511
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and physical characterization of poly(ethylene glycol)-gelatin conjugates.
Kushibiki T; Matsuoka H; Tabata Y
Biomacromolecules; 2004; 5(1):202-8. PubMed ID: 14715027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
